It is thought that more than half of the cases of recurrent IDH‐mutant gliomas develop secondary mismatch repair (MMR) deficiency, as a resistance mechanism to temozolomide (TMZ) [12], which is the most commonly used chemotherapeutic agent in treatment protocols of glioma (together with radiotherapy, following surgery) [13]. This evidence concerns the gene IDH2 and central nervous system cancer.